Details of the Drug Combination

General Information of Drug Combination (ID: DCBUFA4)

• Drug Combination Name: Desoxycorticosterone Pivalate + Arfolitixorin
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Desoxycorticosterone Pivalate (DMSA4B3): Small molecular drug
  Arfolitixorin (DMIXMYK): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 2.68
  Bliss Independence Score: 2.68
  Loewe Additivity Score: 4.53
  LHighest Single Agent (HSA) Score: 4.53

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Desoxycorticosterone Pivalate

Disease Entry	ICD 11	Status	REF
Addison disease	5A74.0	Approved	[2]

Desoxycorticosterone Pivalate Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Mineralocorticoid receptor (MR)	TT26PHO	MCR_HUMAN	Binder	[4]

Desoxycorticosterone Pivalate Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]

Indication(s) of Arfolitixorin

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 3	[3]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Drug information of Desoxycorticosterone Pivalate, 2008. eduDrugs.
• [3] ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
• [4] Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51.
• [5] Progress in Brain Research. Chapter 11 - Steroidogenic Enzymes in the Brain: Morphological Aspects. 2010, 181:193-207.